Latest Media Releases (Page 2) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Arovella Therapeutics licenses novel CAR-iNKT cell armouring technology (ASX:ALA)

-- Arovella has entered into a global, exclusive license with University of North CarolinaLineberger Comprehensive Cancer Center to incorporate a novel armouring cytokinetechnology (IL-12-TM) for it...read more

Careteq - Q2-FY24 activities report & appendix 4C (ASX:CTQ)

Careteq Limited (ASX: CTQ) (“Careteq” or “the Company”), a leading innovator in remote monitoring and healthcare technology, is pleased to provide the following quarterly upd...read more

Arovella Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:ALA)

To view the report, download the attached PDF.

Careteq acquires Home Medicines Review platform (ASX:CTQ)

Highlights Acquisition of first-to-market Home Medicines Review software platform, a marketplace that connects general practitioners (“GPs”) to pharmacists Expec...read more

Arovella Therapeutics receives R&D tax credit of $1.94 million (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that it has received its FY202...read more

CARETEQ - Q1-FY24 ACTIVITIES REPORT & APPENDIX 4C (ASX:CTQ)

Careteq Limited (ASX: CTQ) (“Careteq” or “the Company”), a leading innovator in remote monitoring and healthcare technology, is pleased to provide the following quarterl...read more

Arovella Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:ALA)

MELBOURNE, AUSTRALIA 27 October 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treat...read more

Arovella - Notice of Annual General Meeting/Proxy Form (ASX:ALA)

Date: Friday 10 November 2023 Time: 11:00 am AEDT Registration starts from 10:30 AEDT Location: Virtual meeting by webinar For more information, please download the PDF.

Arovella Therapeutics - Reinstatement to Quotation (ASX:ALA)

Description The suspension of trading in the securities of Arovella Therapeutics Limited (‘ALA’) will be lifted immediately, following the release by ALA of an announcement in relatio...read more

Arovella licenses novel solid tumour targeting technology (ASX:ALA)

Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting a validated target, Claudin 18.2 (CLDN18.2), which is...read more

Arovella Therapeutics - Trading Halt (ASX:ALA)

Description The securities of Arovella Therapeutics Limited (‘ALA’) will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherw...read more

Careteq advances towards FY24 subscriber target (ASX:CTQ)

Investment highlights: Careteq receives 1,500-unit TEQ-Secure order from ADT New Zealand, a subsidiary of Intelligent Monitoring Group (ASX: IMB) Delivery expected early November and o...read more

Arovella Therapeutics - Appendix 4E and Annual Report (ASX:ALA)

To view the report, download the attached PDF.

Arovella Therapeutics - Response to ASX Price Query (ASX:ALA)

For more information, download the attached PDF.

Careteq - Appendix 4E (ASX:CTQ)

To view the Appendix 4E, download the attached PDF.

Viewing: 16 - 30 of 200 Previous | Next